



**FOR IMMEDIATE RELEASE**

**Media Contact:**

Shelley Parnell, VisionGate  
602.354.8222/480.703.9268 (cell)  
[parnell@visiongate3d.com](mailto:parnell@visiongate3d.com)

**VisionGate's First Product, LuCED<sup>®</sup>, Shows Promise for  
Screening of Lung Cancer**

***Company Presents Blinded Trial Data at WCLC 2015  
Demonstrating that Its Non-Invasive Test Detects Early Lung Cancer***

PHOENIX, Ariz. (Sept. 8, 2015) – VisionGate, Inc., a next generation biotech company that has developed a revolutionary, non-invasive test for the early detection of lung cancer, delivered results of its blinded clinical study yesterday evening at the 16<sup>th</sup> World Conference on Lung Cancer being held September 6-9, 2015 at the Colorado Convention Center in Denver, CO.

VisionGate's blinded clinical study of the proprietary LuCED<sup>®</sup> test included 84 patients and demonstrated 92% sensitivity to lung cancer and 98% specificity. "When validated in larger trials, we are cautiously optimistic that this clinical performance would position LuCED as a lung cancer screening tool with the ability to serve populations beyond the highest-risk patients who meet CMS guidelines," VisionGate Founder and Chief Executive Officer Alan Nelson, PhD said.

More than half the people with lung cancer die within one year after being diagnosed, according to the American Lung Association. Described as the "Deadliest Cancer Worldwide," symptoms of lung cancer do not appear until the disease is already in an advanced, non-curable stage.

Spontaneously produced sputum from 36 patients with biopsy confirmed lung cancer and 48 patients who were understood to be cancer free, eight of which suffered from either COPD or emphysema, were included in the study. The LuCED test generated 3D cell image data for blinded cytology review. From this review, 33/36 cancer cases were found to have abnormal cells yielding 92% sensitivity. For the normal cases, 47 cases had no abnormal cells for an estimated 98% specificity. Importantly, this equates to a Negative Predictive Value (NPV) of 99.9% in a population with 1% incidence of lung cancer. VisionGate has begun to conduct large-scale clinical studies to strengthen LuCED's clinical evidence and is pursuing FDA clearance through a national multi-center trial.

"The data from our blinded trial is compelling. We are encouraged – now more than ever – that we are developing a cost-effective solution for detecting lung cancer early," Nelson said. "This is a test which after validation in prospective trials will complement lung cancer screening for the diagnosis of indeterminate nodules seen on the CT scans and perhaps aid in early detection of the disease in high risk individuals."

VisionGate's LuCED test is a physician-ordered, non-invasive take-home test that collects sputum samples for lung cancer analysis. LuCED harnesses the power of proprietary optics and computational technology with the capability to generate 3D images of each cell in a sputum sample. It then automatically analyzes cells to identify key features, or biosignatures, associated with malignancy. This approach should also enable LuCED to identify dysplasia and distinguishes cells as they are turning cancerous. With 127 patents in 13 countries, VisionGate expects to play a leading role in the battle against the world's number one cancer killer.

As of May 2015, VisionGate's LuCED is being offered as a Laboratory Developed Test (LDT) exclusively through the VisionGate Biosignature Laboratories, a Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Phoenix, Arizona. The LuCED test is a diagnostic tool to help inform physician decisions regarding early lung cancer early detection.

"We're excited to have commercialized LuCED this year," VisionGate President Scarlett Spring said. "Physicians are asking for a safe, easily implemented, cost-effective diagnostic tool to help manage false positives from LDCTs. We believe that LuCED is a component to the solution."

VisionGate is headquartered in Phoenix with a Research & Development office in Seattle, Washington. For more information about VisionGate, visit [www.visiongate3d.com](http://www.visiongate3d.com).

###

### **About VisionGate**

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously developed the world's first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. The wholly owned VisionGate Biosignature Laboratories (VBL) offers LuCED, a non-invasive diagnostic test for early-stage lung cancer detection with exquisite sensitivity and specificity. This take-home sputum test is processed on the world's first 3D cell imaging platform, the Cell-CT, named aptly because it is similar in principle to taking a CT scan of individual cells, but using visible light without harmful radiation.

### **Forward-looking statements:**

This press release includes forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development and activity of the Company's first product LuCED as well as the structure of our planned or pending clinical trials. The words "anticipated," "appears," "believe," "continue," "could," "estimate," "expected", "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of the Company's product candidates and preliminary or interim data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that data may not be available when we expect it to be, that enrollment of clinical trials may take longer than expected, that our product candidates will cause unexpected safety events, that the Company will be unable to successfully initiate or complete the clinical development of its product candidates, that the development of the Company's product candidates will take longer or cost more than planned, and that the Company's product candidates will not receive regulatory approval or become commercially successful products. The forward-looking statements contained in this press release reflect the Company's current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.